PARIS, FRANCE, 4 September 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) announced
today the co-optation of Pascal Touchon to its Board as an independent director,
effective 4 October 2023, following the decision of Paul Sekhri to step down
from his director role on this date due to other professional commitments.
Pascal Touchon is an experienced biotech CEO and pharma leader and is the CEO of
ATARA Biotherapeutics. He has previously held leadership positions at Novartis
and Servier and has served on the Board of Directors of several biotechs. He
brings with him a successful track record in US biotech and global pharma, with
30-plus years of experience. He is a graduate of INSEAD, where he received his
MBA.
Following this co-optation, the Board of Directors will remain composed of
fourteen directors: seven women(1) and seven men, including four independent
directors and two directors representing the employees.
Pascal Touchon will be a member of the Nomination Committee, the Innovation and
Development Committee and the Audit Committee.
At the next Shareholder's meeting there will be a request for ratification of
this decision, which would remain in effect for the remainder of Paul Sekhri's
term of office, until the 2026 Shareholder's meeting.
On behalf of the Board of Directors, Chairman of the Board Marc de Garidel
thanks Paul Sekhri for his strong contribution and involvement to Ipsen's Board
and Committees over the last five years.
ENDS
About Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative
medicines in Oncology, Rare Disease and Neuroscience. With total sales of EUR3.0bn
in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-
innovation strategy, the Company's research and development efforts are focused
on its innovative and differentiated technological platforms located in the
heart of leading biotechnological and life-science hubs: Paris-Saclay, France;
Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300
colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S.
through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
For more information, visit ipsen.com (https://www.ipsen.com)
For further information:
Contacts
Investors
Craig Marks Nicolas Bogler
Vice President, Investor Relations Senior Manager, Investor Relations
+44 (0)7584 349 193 +33 6 52 19 98 92
Media
Amy Wolf Ioana Piscociu
VP, Head of Corporate Brand Strategy Senior Manager
& Communications Global Media Relations
+41 79 576 07 23 +33 6 69 09 12 96
Ipsen's forward-looking statements
The forward-looking statements, objectives and targets contained herein are
based on Ipsen's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen's future ability
to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words 'believes', 'anticipates' and 'expects' and similar expressions are
intended to identify forward-looking statements, including Ipsen's expectations
regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking
into account external-growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend on conditions
or facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. Ipsen must face or might face competition from generic
medicine that might translate into a loss of market share. Furthermore, the
research and development process involves several stages each of which involves
the substantial risk that Ipsen may fail to achieve its objectives and be forced
to abandon its efforts with regards to a medicine in which it has invested
significant sums. Therefore, Ipsen cannot be certain that favorable results
obtained during preclinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can
be no guarantees a medicine will receive the necessary regulatory approvals or
that the medicine will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation; global trends
toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Ipsen's patents and other protections for
innovative medicines; and the exposure to litigation, including patent
litigation, and/or regulatory actions. Ipsen also depends on third parties to
develop and market some of its medicines which could potentially generate
substantial royalties; these partners could behave in such ways which could
cause damage to Ipsen's activities and financial results. Ipsen cannot be
certain that its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of Ipsen's partners
could generate lower revenues than expected. Such situations could have a
negative impact on Ipsen's business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this press release
to reflect any change in events, conditions, assumptions or circumstances on
which any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen's latest Universal Registration Document, available on ipsen.com
(https://www.ipsen.com).
--------------------------------------------------------------------------------
(1) Representing 42%, the Directors representing the employees not being taken
into account in this calculation, pursuant to article L. 225-18-1 of the French
Code of Commerce
Â